Camptothecin and Its Analogs
1996; Wiley; Volume: 803; Issue: 1 Linguagem: Inglês
10.1111/j.1749-6632.1996.tb26391.x
ISSN1749-6632
AutoresFranco M. Muggia, Isaiah W. Dimery, Susan G. Arbuck,
Tópico(s)Neutropenia and Cancer Infections
ResumoAnnals of the New York Academy of SciencesVolume 803, Issue 1 p. 213-223 Camptothecin and Its Analogs An Overview of Their Potential in Cancer Therapeutics FRANCO M. MUGGIA, FRANCO M. MUGGIA Department of Medicine and Developmental Therapeutics Program University of Southern California-Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles, California 90033Search for more papers by this authorISAIAH DIMERY, ISAIAH DIMERY Department of Medicine and Developmental Therapeutics Program University of Southern California-Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles, California 90033Search for more papers by this authorSUSAN G. ARBUCK, SUSAN G. ARBUCK Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Diagnosis, Treatment, and Centers National Cancer Institute Bethesda, Maryland 20205Search for more papers by this author FRANCO M. MUGGIA, FRANCO M. MUGGIA Department of Medicine and Developmental Therapeutics Program University of Southern California-Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles, California 90033Search for more papers by this authorISAIAH DIMERY, ISAIAH DIMERY Department of Medicine and Developmental Therapeutics Program University of Southern California-Kenneth Norris Jr. Comprehensive Cancer Center Los Angeles, California 90033Search for more papers by this authorSUSAN G. ARBUCK, SUSAN G. ARBUCK Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Diagnosis, Treatment, and Centers National Cancer Institute Bethesda, Maryland 20205Search for more papers by this author First published: December 1996 https://doi.org/10.1111/j.1749-6632.1996.tb26391.xCitations: 28AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Gottlieb, J. A., A. M. Guarino, J. B. Call, B. T. Oliverio & J. B. Block. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 50: 461– 479. 2 Muggia, F. M., P. J. Creaven, H. H. Hansen, M. H. Cohen & O. S. Selawry. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 56: 515– 521. 3 Moertel, C. G., A. J. Schutt, R. J. Reitemeier & R. G. Hahn. 1972. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56: 95– 101. 4 M. Potmesil & H. Pinedo, Eds. 1995. Camptothecins: New Anticancer Agents. CRC Press. Boca Raton , FL . 5 McGuire, W. P., W. J. Hoskins & M. Brady, 1996. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Eng. J. Med. 334(2): 1– 6. 6 Takeuchi, S., H. Takamizawa, Y. Takeda, T. Okawa, T. Tamaya, K. Noda, T. Sugawa, K. Seriba, M. Yakushiji & T. Taguchi. 1991. Clinical study of CPT-11, a camptothecin derivative, on gynecological malignancy. Proc. Am. Soc. Clin. Oncol. 10: 189. 7 Takeuchi, S., K. Dobashi, S. Fujimoto, K. Tanaka, M. Suzuki, Y. Terashima, K. Hasumi, K. Akiya, Y. Negishi & T. Tamaya. 1991. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn. J. Cancer Chemother. 18: 1681. 8 Ogawa, M. & T. Taguchi. 1992. Clinical studies with CPT-11: The Japanese experience. Ann. Oncol. 3 (Suppl. 1): 118 (A239). 9 Kudelka, A. P., D. Tresukosol, C. L. Edwards, R. S. Freedman, C. Levenback, P. Chantarawiroj, C. Gonzalez De Leon, E. E. Kim, T. Madden, B. Wallin, M. Hord, C. Verschraegen, M. Raber & J. Kavanagh. 1996. Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14: 1552– 1557. 10 Armstrong, D., E. Rowinsky, R. Donehower, N. Rosenshein, J. Walczak, W. McGuire 1995. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 14: 275, (A769). 11 Hochster, H., L. Liebes, J. Speyer, J. Sorich, B. Taubes, R. Oratz, J. Wernz, A. Chachoua, B. Raphael, R. Z. Vinci & R. H. Blum. 1994. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and welltolerated regimen. J. Clin. Oncol. 12: 553– 559. 12 Rowinsky, E., L. B. Grochow, D. S. Ettinger, S. E. Sartorius, B. G. Lubejko, T. L, Chen, M. K. Rock & R. C. Donehower. 1994. Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxycamptothecin (CPT-11) administered as a ninety minute infusion every 3 weeks. Cancer Res. 54(2): 427– 36. 13 Plaxe, S., R. Christen, J. O'Quigley, P. Braly, J. Freddo, E. McClay, D. Heath & S. Howell. 1993. Phase I trial of intraperitoneal topotecan. Proc. Am. Soc. Clin. Oncol. 12: 140 (A360). 14 Kavanagh, J. J. 1994. CPT-11 (irinotecan) in refractory squamous cell carcinoma of the cervix. Proc. Am. Assoc. Clin. Res. 35: A1397. 15 Chevalier, B., C. Lhomme, V. Dieras, P. H. Vennin, J. Chauvergne, P. Rebattu, P. Fumoleau, H. Roche, Y. Krakowski, M. A. Lentz, A. Mathieu & M. Van Glabbecke 1995. Phase II trial of CPT-11 in advanced cervical carcinoma. Proc. Am. Soc. Clin. Oncol. 14: 267, A737. 16 Potkul, R. K., F. V. Price, H. Bailey, M. Gelder, R. Rosenbluth & H. J. Durivage. 1995. Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (Phase II). Proc. Am. Soc. Clin. Oncol. 14: A785. 17 Fukuoka, M., H. Niitani, A. Suzuki, M. Motomiya, K. Hasagawa, Y. Nishiwaki, T. Kuriyama, Y. Ariyashi, S. Negoro, N. Masuda, S. Nakajima & T. Taguchi. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16– 20. 18 Mori, K., U. Suga, I. Kishiro, S. Ohto & K. Tominaga. 1994. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 335. 19 Douillard, J. W., N. Ibrahim, A. Riviere, D. Spaeth, P. Chomy, K. Soussan & A. Mathieu-Boue. 1995. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC) Proc. Am. Soc. Clin. Oncol. 14: 365 (#1118). 20 Masuda, N., M. Fukuoka, M. Takada, Y. Kusunoki, S. Negoro, K. Matsui, S. Kudoh, N. Takifuji, K. Nakagawa & S. Kishimoto. 1992. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J. Clin. Oncol. 10: 1775– 80. 21 Weith, J. J., S-H. Jung, R. F. Marschke, Jr., T. R. Fitch & J. R. Jett. 1995. Randomized phase II trial of two dose schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma: A North Central Cancer Treatment Group (NCCTG) trial. Proc. Am. Soc. Clin. Oncol. 14: 348 (A1053). 22 Perez-Soler, R., F. V. Fossella, B. S. Glisson, W. K. Murphy, D. M. Shin, B. L. Kemp, J. Lee, J. Kane, R. A. Robinson, S. M. Lippman, J. M. Kurie, M. H. Huber, M. N. Raber & W. K. Kong. 1996. Phase II study of Topotecan in patients with advanced previously untreated non-small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14: 503– 513. 23 Lynch, T. J. Jr., L. Kalish, G. Strauss, A. Elias, A. Skarin, L. N. Schulman, M. Posner & E. Frei, III. 1994. Phase II study of topotecan in metastatic non-small cell lung cancer. J. Clin. Oncol. 12: 347– 352. 24 Graham, M. V., M. Jahanzeb, C. Dresler, J. Cooper, B. Emami, J. Mortimer 1994. Preliminary results of a phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 340 (A1132). 25 Negoro, S., M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, H. Niitani & T. Taguchi. 1991. Phase I clinical study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst. 83: 1164– 1169. 26 Masuda, N., M. Fukuoka, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, S. Negoro, M. Nishioka, K. Nakagawa & M. Takada. 1992. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 10: 1225– 1229. 27 Fujiwara, Y., M. Yamakido, M. Fukuoka, S. Kudoh, K. Juruse & H. Ikegami. 1994. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 335 (A1110). 28 Negoro, S. 1993. Phase I study of irinotecan (CPT-11) and etoposide with G-CSF in advanced lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 133 (A331). 29 Wanders, J., A. Ardizzoni, H. Hansen, Dombernowsky, P. E., Postmus, M. Buitenhuis, M. MacDonald, G. Giaccone & J. Verweij. 1994. Phase II study of topotecan in refractory and sensitive small cell lung cancer. Proc. Assoc. Cancer Res. 36: 237 (A1415). 30 Perez-Soler, R., B. S. Glisson, J. S. Lee, F. V. Fossella, S. M. Lippman, M. H. Huber, D. M. Shin, W. K. Murphy & W. K. Hong. 1995. Phase II study of topotecan in patients with small cell lung cancer refractory to etoposide. Proc. Am. Soc. Clin. Oncol. 14: 355 (A 1078). 31 Eckardt, J. R., H. A. Burris, G. A. Rodriguez, et al. 1993. A Phase I study of the topoisomerase I and II inhibitors Topotecan and etoposide. Proc. Am. Soc. Clin. Oncol. 11: 138. 32 Schiller, J., K. Kim & D. Johnson for the Eastern Cooperative Oncology Group. 1994. Phase II study of topotecan in extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 330 (A1093). 33 Dimery, I., J. H. Doroshow, D. Gandara & F. Muggia. 1996. Phase II trial of 9-aminocamptothecin in small cell lung cancer. Unpublished. 34 Tsuda, H., K. Takatsuki, R. Ohno, T. Masaoka, K. Okada, S. Shirakawa, Y. Ohashi, K. Ohta & T. Taguchi. 1992. A late phase II trial of potent topoisomerase 1 inhibitor, CPT-11, in malignant lymphomas. Proc. Am. Soc. Clin. Oncol. 11: 316. 35 Ohno, R., K. Okada, T. Masaoka, A. Kuramoto, T. Arima, Y. Yoshido, A. Ariyoshi, M. Ichimaru, Y. Sakai, M. Oguro, Y. Ito, Y. Morishima, S. Yokomaku & K. Ota. 1990. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907. 36 Preti, H. A. W., Plunkett, A. H., Sarris, A. Younes, F. Hagemeister, M. A. Rodriguez, J. Romaguera, P. McLaughlin, C. Bachier & F. Cabanillas. 1995. Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma. Blood 86 (10, Suppl. 1): 820a (A3268). 37 Kraut, E., K. Crowley, J. Wade, L. Laufman, G. Weiss, S. Taylor & S. Salmon. 1995. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. Blood 86 (10, Suppl. 1): 185a (A726). 38 Beran, M., S. O'Brien, S. Arbuck, S. Pierce, M. Keating & H. Kantarjian. 1995. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 86 (10, Suppl. 1): 337a (A1335). 39 Oguro, M., Y. Seki, K. Okada & T. Andoh. 1990. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed. & Pharmacother. 44: 209– 216. 40 Wall, M. E. 1969. Alkaloids with antitumor activity. In Proceedings of the International Symposium on Biochemistry and Physiology Alkaloide. Berlin . Akademic Verlag, pp. 77– 87. 41 Hinz, H. R., N. J. Harris, E. A. Natelson & B. C. Giovanella. 1994. Pharmacokinetics of the in vivo and in vivo conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res. 54(11): 3096– 3100. 42 McCabe, F. L. & R. K. Johnson. 1994. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest. 12(3): 308– 13. 43 Van De Zee, A. G. J., S. de Jong, W. N. Keith, H. Hollema, A. Boonstra & E. G. Ede Vries 1994. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 54: 149– 155. 44 Goldwasser, F., I. Bae, M. Valenti, K. Torres & Y. Pommier. 1995. Topoisomerase 1-related parameters and camptothecin activity in colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55: 2116– 21. 45 Tsao, Y-P, P. D'Arpa & L. F. Liu. 1992. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc 2/cyclin B. Cancer Res. 52(7): 1823– 1829. 46 Burris, H. A., III, A-R. Hanauske & R. K. Johnson et al. 1992. Activity of topotecan, a new topoisomerase 1 inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. 84: 1816– 1820. 47 Pantazis, P. A. J. Kozielski, J. T. Mendoza, J. A. Early, H. R. Hinz & B. C. Giovanella. 1993. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53: 863– 871. 48 Kanzawa, F., Y. Sugimoto, K. Minato, K. Kasahara, M. Bungo, K. Nakagawa, Y. Fujiwara, L. F. Liu & N. Saijo. 1990. Establishment of camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50: 6919– 6924. 49 Niimi, S., K. Nakagawa, Y. Sugimoto, K. Nishio, Y. Fujiwara, S. Yokoyama, Y. Terashima & N. Saijo. 1992. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 52: 328– 333. 50 Katz, E. J., J. S. Vick, K. M. Kling, et al. 1990. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur. J. Cancer 26: 724– 727. 51 Mattern, M. R., G. Hoffman, F. McCabe, et al. 1991. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan. Cancer Res. 51: 5813– 5816. 52 Kudoh, S., M. Takada, M. Masuda, K. Nagakawa, K. Itoh, Y. Kusunoki, S. Negoro, K. Matsui, N. Takifuji & H. Morino. 1993. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. 84: 203– 7. 53 Kawato, Y., M. Aounuma, Y. Hiroto, H. Kuga & K. Sato. 1991. Intracellular role of SN-38. a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51: 4187– 4191. 54 Rothenberg, M. L., H. A. Burris, III, J. R. Eckardt, D. A. Rinaldi, G. R. Weiss, S. Smith, K. Jones, R. K. Johnson & D. D. von Hoff 1993. Phase I/II of topotecan + cisplatin in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 156 (A423). 55 Mastda, N., M. Fukuoka, S. Kudoh, K. Matsui, Y. Kusunoki, M. Takada, K. Nakagawa, T. Hirashima, H. Tsukada, T. Yana, A. Yoshikawa, A. Kubo, E. Maqtsuura, T. Niita, N. Takifuji, K. Terakawa & S. Negoro. 1994. Phase I and pharmacologic study of irinotecan and cisplatin with granulocyte-colony stimulating factor support for advanced lung cancer. J. Clin. Oncol. 12: 1833– 1841. 56 Hendricks, C. B., E. K. Rowinsky, L. B. Grochow, R. C. Donehower & S. H. Kaufman. 1992. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52: 2268– 2278. 57 Tsuruo, T., T. Matsuzaki, M. Mtsushita, H. Saitos & T. Yokokura. 1988. Antitumor effects of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71– 74. 58 Mutsui, I., E. Kumazawa, Y. Hirota, M. Aonuma, M. Sugimori, S. Ohsuki, K. Uoto, A. Ejima, H. Terasawa & K. Sato. 1995. A new water soluble camptothecin derivative, DX-7951f, exhibits potent antitumor activity against human tumor in vitro and in vivo. Jpn. J. Cancer Res. 86: 776– 782. 59 Gupta, E., T. M. Lestingi, R. Mick, J. Ramirez, E. E. Vokes & M. J. Ratain. 1994. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723– 3725. 60 Gupta, E., A. R. Safa & M. J. Ratain. 1995. P-glycoprotein mediated excretion of CPT-11 and SN-38: Effect of cyclosporine A. Proc. Am. Soc. Clin. Oncol. 14: 490 (A 1602). 61 Takimoto, C. & S. G. Arbuck. 1996. The camptothecins. In Cancer Chemotherapy and Biotherapy, Principles and Practice, second edition, Lippincott. B. A. Chabner & D. L. Longo, Eds. 463– 484 Raven Press, New York . 62 Sugiyama, T., T. Nishida, K. Ushijima, S. Kumagai & M. Yskushiji. 1996. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15: 291 (#796). 63 Shimizu, Y., S. Umezawa & K. Hasumi. 1996. Combination of CPT-11 (CPT) with mitomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant. Proc. Am. Soc. Clin. Oncol. 15: 282 (#761). 64 Hochster, H., J. Speyer, S. Wadler, C. Runowicz, R. Wallach, R. Oratz, A. Chachoua, J. Sorich, B. Taubes, E. Ludwig, C. Broom & R. Blum. 1996. Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: A highly active regimen. Proc. Am. Soc. Clin. Oncol. 15: 285 (#775). 65 Ten Bokkel Huinink, W., M. Gore, G. Bolis, J. Verweij, J. Lacave, G. Scarfone, J. Guastalla, S. van Bella, R. Despax, G. Favalli, I. Hudson & R. Kreinberg. 1996. A phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 15: 284 (#768). 66 Gordon, A., M. Bookman, H. Malmstrom, G. Bolis, C. Mangioni, J. Hall, J. Carter, I. Hudson & C. Broom. 1996. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol. 15: 282 (#763). 67 Carmichael, J., A. Gordon, J. Malfetano, M. Gore, M. Spacynski, N. Davidson, J. Savage, D. Clarke-Pearson, J. Hudson, C. Broom & W. ten Bokkel Huinink 1996. Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol. 15: 283 (#765). 68 Malstrom, H., B. Sorbe & E. E. Simonsen. 1996. The effect of Topotecan in platinum refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15: 229 (#829). 69 Ando, M., K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe, N. Yamamoto, Y. Kurata, T. Kasai, H. Omatsu, K. Kubota, T. Sekine, S. Hojo, T. Matsumoto, R. Kakinuma, Y. Nishiwaki & N. Saijo. 1996. Phase I study of sequentially administered CPT-11 and VP-16 for metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 15: 480 (#1522). 70 Kudoh, S., N. Kurihara, K. Okishio, K. Hirata, J. Yoshikawa, N. Masuda, M. Takada, K. Takeda, S. Negoro & M. Fukuoka. 1996. A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 15: 372 (#1102). 71 Ansari, R. H., G. A. Masters, P. C. Hoffman, C. Hoehne, R. Critchlow, D. Sciortino, J. W. Kuglar, M. J. Ratain, H. M. Golomb & E. E. Vokes. 1996. A phase II trial of 9-aminocamptothecin (9-AC) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 15: 408 (#1247). Citing Literature Volume803, Issue1The Camptothecins: From Discovery to the PatientDecember 1996Pages 213-223 ReferencesRelatedInformation
Referência(s)